Mitigating Cutaneous Toxicity in Patients Undergoing TomoTherapy; A Randomized Controlled Trial of Skin-Protective Strategies
The study, sponsored by King Faisal Specialist Hospital & Research Center, aims to evaluate two skin-protective strategies for head and neck cancer patients undergoing TomoTherapy. Given the high incidence of radiation dermatitis (up to 84%) in this patient population, successful outcomes could position the selected intervention as a standard of care, potentially capturing a significant share of the supportive care market in oncology. The products being tested are affordable and widely available, which may facilitate adoption in clinical practice. However, the lack of established standards for managing radiation dermatitis presents both a challenge and an opportunity for differentiation in a competitive landscape dominated by traditional supportive care approaches.
Indication: Head and Neck Cancer
Modality: medical device
Target: Fragrance-free emollient (glycerol-based) and silicone-based semi-permeable barrier film for skin protection in radiation therapy.
Sponsor: King Faisal Specialist Hospital & Research Center
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 21, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Fragrance-free emollient (glycerol-based) and silicone-based semi-permeable barrier film for skin protection in radiation therapy.
View original source fields
Condition raw: Head and Neck Cancer
Condition normalized: Head and Neck Cancer
Modality raw: medical device
Modality normalized: medical device
Target raw: Fragrance-free emollient (glycerol-based) and silicone-based semi-permeable barrier film for skin protection in radiation therapy.
Target normalized: Fragrance-free emollient (glycerol-based) and silicone-based semi-permeable barrier film for skin protection in radiation therapy.